Literature Review

All posts tagged with “Research News.”



Cancer prevention, screening averted several million more deaths than treatment over 45 years

01/11/25 at 03:05 AM

Cancer prevention, screening averted several million more deaths than treatment over 45 yearsJAMA; Samantha Anderer; 1/25In the US, cancer prevention and screening have saved more lives from 5 types of cancer combined than treatment advances over the past 45 years, according to a modeling study published in JAMA Oncology. An estimated 5.9 million breast, cervical, colorectal, lung, and prostate cancer deaths were avoided from 1975 to 2020 due to prevention, screening, and treatment efforts, but prevention and screening alone were responsible for averting about 4.8 million—4 out of 5—of those deaths. Still, the authors acknowledged that in all cancer types studied, less than half of total cancer deaths were averted, and they recommended increased investment in prevention and screening strategies.

Read More

Provider perspectives on implementation of adult community-based palliative care: A scoping review

01/11/25 at 03:00 AM

Provider perspectives on implementation of adult community-based palliative care: A scoping reviewMedical Care Research and Review; Nicole Dussault, Dorian Ho, Haripriya Dukkipati, Judith B. Vick, Lesley A. Skalla, Jessica Ma, Christopher A. Jones, Brystana G. Kaufman; 1/25While community-based palliative care (CBPC) programs have been expanding, there remain important obstacles to widespread use. Since provider perspectives on CBPC remain underexplored, we conducted a scoping review to summarize provider perspectives regarding barriers and facilitators to implementation of adult CBPC in the United States. At the provider level, barriers included misperceptions of palliative care (PC) by referring providers and poor communication, while facilitators included multidisciplinary teams and referring provider education. At the organizational level, time constraints were barriers, while leadership buy-in and co-located clinics were facilitators. At the external environment level, limited PC workforce and inadequate reimbursement were barriers. Our findings suggest that efforts aimed at scaling CBPC must address factors at the provider, organizational, and policy levels.

Read More

Re-imagining childhood grief: Children as active agents in a transactional process

01/04/25 at 03:35 AM

Re-imagining childhood grief: Children as active agents in a transactional processOmega-Journal of Death and Dying; Ceilidh Eaton Russell, Meg Chin, Georg Bollig, Cheryl-Anne Cait, Franco A. Carnevale, Jody Chrastek, Bianca Lavorgna, Catriona Macpherson, Stacy S. Remke, Lies Scaut, Jane Skeen, Regina Szylit, Camara van Breemen, Ronit Shalev; 12/24While undoubtedly, the death of a parent or sibling causes considerable distress for children, the transactional model argues that an individual’s ability to adapt to challenges and problems arises from the transactions - interactions - that occur between them and their environment (Sameroff, 2009). After a loss, it is critical to be aware of the fact that children do grieve, that they impact and are impacted by those around them, reflecting influences on their social environments at any and every age. Their impressions, the feedback they receive, the messages they interpret about what is and is not deemed acceptable by those around them, can have immediate and life-long influences on their thoughts, behaviours, emotional and physical wellbeing. We propose that rather than placing the burden solely on children to seek support, adults have responsibilities to engage in a collaborative process whereby children have opportunities to express their interests and needs.

Read More

Head and neck cancer mortality in the Appalachian region

01/04/25 at 03:30 AM

Head and neck cancer mortality in the Appalachian regionJAMA Otolaryngology-Head and Neck Surgery; Todd Burus, MAS; Pamela C. Hull, PhD; Krystle A. Lang Kuhs, PhD, MPH; 12/24In contrast to non-Appalachian US, where HNC [head and neck cancer] mortality rates declined considerably between 1999 and 2020, HNC mortality rates in the Appalachian region have remained stubbornly stable. Moreover, statistically significant increasing rates of HNC mortality in rural Appalachia provide evidence that the lack of rural HNC mortality improvements nationwide are associated with Appalachian disparities. While the exact factors driving these trends are unknown, the Appalachian region has an increased prevalence of multiple risk factors associated with cancer mortality, such as adverse social determinants of health, heightened alcohol and tobacco use, later stage at diagnosis, and limited access to care. Investments in the Appalachian region—such as through the Bipartisan Infrastructure Law or by expanding coverage of the National Cancer Institute’s Surveillance, Epidemiology, and End Results Program among Appalachian states—could help reduce the burden of HNC mortality by improving cancer surveillance and serving the unique needs and experiences of the Appalachian population. These investments could also aid efforts to improve other cancer sites with known disparities in Appalachia, such as lung and colorectal cancers.

Read More

Methadone in cancer-related neuropathic pain: A narrative review

01/04/25 at 03:25 AM

Methadone in cancer-related neuropathic pain: A narrative reviewCurrent Oncology; Faten Ragaban, Om Purohit, Egidio Del Fabbro; 12/24The unique mechanisms of action and preliminary clinical trials support methadone's status as the first opioid to consider for CRNP [cancer-related neuropathic pain] when non-opioid first-line treatments have failed to alleviate patient symptoms. Methadone can also be considered as a first-line opioid in patients with mixed nociceptive-neuropathic pain and any of the following features: renal dysfunction; administration of opioids through a feeding tube; a lack of financial resources/insurance; and a switch from another high-dose opioid. More research is needed regarding methadone for CRNP and methadone's preferential use in specific sub-groups of patients.

Read More

Current challenges in neurocritical care: A narrative review

01/04/25 at 03:20 AM

Current challenges in neurocritical care: A narrative reviewWorld Neurosurgery; Safa Kaleem, William T. Harris II, Stephanie Oh, Judy H. Ch'ang; 1/25Neurocritical care as a field aims to treat patients who are neurologically critically ill due to a variety of pathologies. As a recently developed subspecialty, the field faces challenges, several of which are outlined in this review ... [including confusion around] brain death testing or the diagnosis of brain death itself ... Given these difficult scenarios encountered in the neuro-ICU, conversations with patients’ decision-makers are often done with the assistance of palliative care services ... the most common reasons for palliative care consultation in the neuro-ICU were discussing prognosis, eliciting patient and family values, understanding medical options, and identifying conflict. Collaboration with hospital chaplains and palliative care services can be helpful, but cultural humility also needs to be a priority for neurocritical care providers to be able to navigate difficult conversations.

Read More

Virtual support for bereaved parents: Acceptability, feasibility, and preliminary efficacy of HOPE group

01/04/25 at 03:15 AM

Virtual support for bereaved parents: Acceptability, feasibility, and preliminary efficacy of HOPE groupJournal of Palliative Medicine; Kristin Drouin, Amelia Hayes, Emma Archer, Elissa G Miller, Aimee K Hildenbrand; 12/24Hospital-based supports for families following the death of a child are rare. Our hospital's palliative care program offered a six-week closed virtual support group for bereaved parents five times between 2021 and 2024. In total, 36 parents (76% women) attended at least one group session and provided data. Participants endorsed high satisfaction with the intervention. This virtual support group was acceptable and feasible for bereaved parents. Additional research with larger, more diverse samples and more robust designs is needed.

Read More

Conscience at the end of life

01/04/25 at 03:10 AM

Conscience at the end of lifeNursing Reports; Ralph Neil Baergen, James Skidmore; 12/24Caring for patients at the end of life can involve issues that are ethically and legally fraught: withholding or withdrawing artificial nutrition and hydration, pain control that could hasten death, aggressive treatment that is continued when it seems only to be prolonging suffering, patients who request medical assistance in dying, and so forth. Clinicians may find that their deeply held ethical principles conflict with law, institutional policy, or patients' choices. In these situations, they may consider either refusing to participate in procedures that they find morally abhorrent (conscientious refusal) or providing care that they believe to be ethically obligatory despite being contrary to law or policy (conscientious commitment). Healthcare providers who refuse to provide medical services should be expected to explain their reasons, make prompt referrals, and bear some of the resulting costs or burdens.

Read More

Nutrition in advanced disease and end of life cancer care

01/04/25 at 03:05 AM

Nutrition in advanced disease and end of life cancer careSeminars in Oncology Nursing; Betty Ferrell, Nathaniel Co, William E. Rosa; 12/24Throughout the cancer continuum—starting at diagnosis and throughout disease-directed treatment, end-of-life care, and survivorship—nutrition screening, counseling, and intervention should be routinely considered integral to care. During cancer treatment, these nutritional components serve as adjuvants to therapy with significant benefits to body composition, quality of life, and survival with improved nutrition. The phases of advanced disease and also end of life care present unique challenges related to nutrition which is the focus of this paper. Providing nutrition is one of the most important aspects of care provided by families for patients with advanced disease with deep meaning in these relationships, especially at the end of life. Oncology nurses provide valuable guidance in these decisions and offer support to both patients and families to ensure quality of life across the trajectory of cancer. 

Read More

Caregiver reported experiences of not-for-profit hospice agencies with a religious affiliation

01/04/25 at 03:00 AM

Caregiver reported experiences of not-for-profit hospice agencies with a religious affiliationJournal of the American Geriatrics Society; by Xiao (Joyce) Wang, Joan M. Teno, Momotazur Rahman, Emmanuelle Belanger; 12/24Compared to those without a religious affiliation, the religiously affiliated hospices were smaller in size, newer, had a higher shares of patients with dementia, and also a higher percentage of patients living in nursing homes, and were more likely to be in the Midwest. These hospices also had lower scores across all CAHPS measures, with the magnitude of these differences by religious affiliation being small to medium. Compared to hospices without a religious affiliation, a much lower proportion of hospices with a religious affiliation received four or five stars (66.5% vs. 47.6%).Publisher's note: While for-profit hospices have been grouped into various categories (e.g., private equity owned or publicly traded companies), this is the first article I recall grouping nonprofit hospices into various categories.

Read More

Trends in private equity acquisition of pain management practices

12/28/24 at 03:45 AM

Trends in private equity acquisition of pain management practicesJAMA Network Open; Geronimo Bejarano, MPH; James E. Eubanks, MD, MS; Robert T. Braun, PhD; 12/24Pain has the highest health care spending in the US and is expected to increase with the aging population, which may entice private equity acquisitions of pain management practices. Private equity has increasingly acquired physician practices and acquisitions are associated with higher spending, utilization of more expensive treatments, and increasing patient volume. In this cross-sectional study of private equity acquisitions of pain management practices, we found a rise in acquisitions over the last decade with almost 1 in 10 pain management physicians affiliated with a private equity–owned pain management practice. [The] ... high amount of consolidation within certain states poses concerns for private equity to have enough market power to control care delivery of several procedure-based specialties, including pain management. Policymakers and the Federal Trade Commission have taken notice of the harms of increases in both health care consolidation and private equity acquisitions, and there are ongoing efforts to curb their detrimental effects. 

Read More

Recommendations to ensure safety of AI in real-world clinical care

12/28/24 at 03:40 AM

Recommendations to ensure safety of AI in real-world clinical careJAMA; Dean F. Sittig, PhD; Hardeep Singh, MD, MPH; 11/24As HCOs [health care organizations] adapt their clinical and administrative workflows to new AI [artificial intelligence]-driven technologies, unintended adverse consequences will inevitably occur, particularly during transitions. To address these risks, HCOs and AI/EHR [electronic health record] developers must collaborate to ensure that AI systems are robust, reliable, and transparent. HCOs must proactively develop AI safety assurance programs that leverage shared responsibility principles, implement a multifaceted approach to address AI implementation, monitor AI use, and engage clinicians and patients. Monitoring risks is crucial to maintaining system integrity, prioritizing patient safety, and ensuring data security. 

Read More

Health systems are struggling to keep up with AI - A national registration system could help

12/28/24 at 03:35 AM

Health systems are struggling to keep up with AI—A national registration system could helpJAMA; Roy Perlis, MD, MSc; Rita Rubin, MA; 12/24This conversation is part of a series of interviews in which JAMA Network editors and expert guests explore issues surrounding the rapidly evolving intersection of artificial intelligence (AI) and medicine. In a Viewpoint published in JAMA this past August, Michael Pencina, PhD, Duke Health’s chief data scientist, argued for a federated registration system for AI and health. Dr Pencina:I strongly believe that every organization needs to know what AI solutions it has implemented. In particular, health systems should keep track of AI algorithms or other AI solutions they’re running in clinical care and clinical operations. Imagine a portal where you record all the AI that you’re running and all the information related to it. Say Duke does it, but another health system does it, and another health system. It becomes national. That opens really interesting opportunities for collaboration, information sharing, and enhancing the ecosystem, as well as transparency for patients, our ultimate stakeholders.

Read More

Evolution in documented goals of care at end of life for adolescents and younger adults with cancer

12/28/24 at 03:30 AM

Evolution in documented goals of care at end of life for adolescents and younger adults with cancerJAMA Network Open; Rosemarie Mastropolo, Colin Cernik, Hajime Uno, Lauren Fisher, Lanfang Xu, Cecile A Laurent, Nancy Cannizzaro, Julie Munneke, Robert M Cooper, Joshua R Lakin, Corey M Schwartz, Mallory Casperson, Andrea Altschuler, Lawrence Kushi, Chun R Chao, Lori Wiener, Jennifer W Mack; 12/24Little is known about the nature of change in goals of care (GOC) over time among adolescents and younger adult (AYA) patients aged 12 to 39 years with cancer near the end of life. Understanding how GOC evolve may guide clinicians in supporting AYA patients in making end-of-life decisions. In this cross-sectional study of AYA patients who died of cancer, palliative goals were rarely documented before the last month of life, highlighting the need for timely and ongoing GOC discussions.

Read More

[London] The problem of value change: Should advance directives hold moral authority for persons living with dementia?

12/28/24 at 03:25 AM

[London] The problem of value change: Should advance directives hold moral authority for persons living with dementia?Bioethics; by Anand Sergeant1; 12/24As the prevalence of dementia rises, it is increasingly important to determine how to best respect incapable individuals' autonomy during end‐of‐life decisions. Many philosophers advocate for the use of advance directives in these situations to allow capable individuals to outline preferences for their future incapable selves. In this paper, however, I consider whether advance directives lack moral authority in in-stances of dementia.

Read More

Behavioral symptoms and treatment challenges for patients living with dementia: Hospice clinician and caregiver perspectives

12/28/24 at 03:20 AM

Behavioral symptoms and treatment challenges for patients living with dementia: Hospice clinician and caregiver perspectivesJournal of the American Geriatrics Society; Karolina Sadowska BA; Molly Turnwald BA; Thomas O'Neil MD; Donovan T. Maust MD, MS; Lauren B. Gerlach DO, MS; 12/24Dementia affects one in three older adults over age 85 and individuals with dementia constitute the fastest growing population of patients entering hospice care. While cognitive impairment is the hallmark of dementia, behavioral symptoms are reported in nearly all patients with advanced dementia, contributing to both the complexity of end-of-life care and caregiver burden. Behavioral symptoms of dementia are highly prevalent among the US hospice population and are often managed with psychotropic medications prescribed off-label. There are limited treatment guidelines in this population, so the appropriate risk and benefit balance may be highly individual. This qualitative study can help to inform the decision-making of hospice clinicians and caregivers regarding anticipated behavioral changes and limitations of treatment options in dementia end-of-life care. 

Read More

Health disparities in hospice - home health transitions in Hispanic older adults with co-occurring dementia and cardiovascular disease

12/28/24 at 03:15 AM

Health disparities in hospice - home health transitions in Hispanic older adults with co-occurring dementia and cardiovascular diseaseAmerican Journal of Hospice and Palliative Care; by Sharon E Bigger, Kathy Howard Grubbs, Yan Cao, Gail L Towsley; 12/24We aimed to determine if there were demographic and/or diagnostic variables associated with the frequency of transitions between skilled HH and hospice... Hispanic older adult beneficiaries with Alzheimer's disease and related dementias (ADRD) and co-occurring cardiovascular disease (CVD) had significantly higher rates of care transitions from hospice to skilled HH than other racial and ethnic groups with both diagnoses... Our findings provide evidence of disparities in care transitions from hospice to skilled HH for Hispanic older adults living with ADRD and CVD.

Read More

Estimation of cancer deaths averted from prevention, screening, and treatment efforts, 1975-2020

12/28/24 at 03:10 AM

Estimation of cancer deaths averted from prevention, screening, and treatment efforts, 1975-2020JAMA Oncology; Katrina A. B. Goddard, PhD; Eric J. Feuer, PhD; Jeanne S. Mandelblatt, MD, MPH; Rafael Meza, PhD; Theodore R. Holford, PhD; Jihyoun Jeon, PhD; Iris Lansdorp-Vogelaar, PhD; Roman Gulati, MS; Natasha K. Stout, PhD; Nadia Howlader, PhD; Amy B. Knudsen, PhD; Daniel Miller, BA; Jennifer L. Caswell-Jin, MD; Clyde B. Schechter, MD; Ruth Etzioni, PhD; Amy Trentham-Dietz, PhD; Allison W. Kurian, MD, MSc; Sylvia K. Plevritis, PhD; John M. Hampton, MS; Sarah Stein, PhD; Liyang P. Sun, MS; Asad Umar, DVM, PhD; Philip E. Castle, PhD; 12/24Overall US mortality has declined over time for most major cancer sites because of progress in prevention, screening, and treatment. Nevertheless, the reignited Cancer Moonshot goal to reduce the age-adjusted cancer mortality rate by 50% in the next 25 years will not be achieved without accelerating progress. In this model-based study using population-level cancer mortality data, an estimated 5.94 million deaths were averted from these 5 cancers [breast, cervical, colorectal, lung, and prostate] combined. Prevention and screening accounted for 8 of every 10 averted deaths, and the contribution varied by cancer site. A comprehensive plan to reduce cancer mortality includes interventions in cancer prevention, detection, diagnosis, treatment, and survivorship care.

Read More

High-risk opioid prescribing and nurse practitioner independence

12/28/24 at 03:05 AM

High-risk opioid prescribing and nurse practitioner independenceJAMA Health Forum; Lucas D. Cusimano, BS; Nicole Maestas, MPP, PhD; 12/24In 2021, more than 1 in 5 opioid overdose deaths were attributed to prescription opioids in the US, and the rate of such deaths has increased 5-fold since 1999. Concerns around excessive opioid prescribing have been used to argue against the expansion of the scope of practice of nurse practitioners (NPs) ... In this difference-in-differences analysis of opioid prescribing in 16 states, there was no change in the rates of high-risk opioid prescribing in the 6 states that adopted nurse practitioner independence compared with 10 nonadopting neighboring states during the 24 months following adoption. The study found no association between legislation that granted independence to nurse practitioners and rates of risky opioid prescribing. 

Read More

Cannabidiol for scan-related anxiety in women with advanced breast cancer - A randomized clinical trial

12/28/24 at 03:00 AM

Cannabidiol for scan-related anxiety in women with advanced breast cancer-A randomized clinical trialJAMA Network Open; Manan M. Nayak, PhD, MA; Peter Chai, MD; Paul J. Catalano, ScD; William F. Pirl, MD, MPH; James A. Tulsky, MD; Stephanie C. Tung, MD; Nancy U. Lin, MD; Nicole Andrade, BA; Sabrina Johns, MPH; Clint Vaz, MD; Melissa Hughes, MSc; Ilana M. Braun, MD; 12/24The findings of this randomized clinical trial show that CBD [cannabidiol] can be used safely in women with advanced breast cancer and clinical anxiety. Although the study did not meet its primary end point comparing preingestion vs postingestion anxiety change scores between study arms, anxiety levels in the CBD arm were significantly lower 2 to 4 hours after ingestion, suggesting a possible anxiolytic effect and warranting further investigation. 

Read More

Silent invader: A rare case of enterobacter aerogenes empyema in a hospice patient with complex comorbidities

12/21/24 at 03:45 AM

Silent invader: A rare case of enterobacter aerogenes empyema in a hospice patient with complex comorbiditiesCureus Case Reports; Hansani Angammana, Kafayat Omadevuae, Victoria Bengualid, Rawand Khader; 11/24Enterobacter aerogenes (recently renamed Klebsiella aerogenes) is an uncommon pathogen in pleural infections and empyema, typically associated with nosocomial urinary and gastrointestinal infections. This case report describes a 69-year-old male patient with chronic kidney disease, diabetes mellitus, and other comorbidities, who developed empyema despite broad-spectrum antibiotics. Despite initial improvement with cefepime and metronidazole, the patient's respiratory status deteriorated, and due to his do not resuscitate/do not intubate (DNR/DNI) status and extensive comorbidities, no further aggressive interventions were pursued, leading to his passing. This case highlights the diagnostic and therapeutic challenges posed by E. aerogenes in pleural infections, emphasizing its rarity in pulmonary involvement and its potential for antibiotic resistance. It also underscores the importance of considering atypical pathogens in complex infections and the need for multidisciplinary management while balancing aggressive treatments with patient-centered care, particularly in end-of-life scenarios.

Read More

Stakeholder perspectives on randomized clinical trials for children with poor-prognosis cancers

12/21/24 at 03:40 AM

Stakeholder perspectives on randomized clinical trials for children with poor-prognosis cancersJAMA Network Open; Nicholas Bird, MSc; Nicole Scobie; Pablo Berlanga, MD; Patricia Blanc, MBA; Vickie Buenger, PhD; Quentin Campbell-Hewson, MBChB; Michela Casanova, MD; Steven DuBois, MD; Julia Glade Bender, MD; Ann Graham; Delphine Heenen, LLM; Christina Ip-Toma, BSc; Donna Ludwinski, BSChem; Lucas Moreno, MD; Donna Neuberg, ScD; Antonia Palmer, MASc; Xavier Paoletti, PhD; Willemijn Plieger-van Solkema, LLM; Gregory Reaman, MD; Teresa de Rojas, MD; Claudia Rossig, MD; Anja Schiel, PhD; Sara Wakeling, BA; Gilles Vassal, MD; Andrew Pearson, MD; Leona Knox, BSc; 12/24In poor-prognosis children’s cancers, new therapies may carry fresh hope for patients and parents. However, there is an absolute requirement for any new therapy to be properly evaluated to fulfill scientific, regulatory, and reimbursement requirements. Randomized clinical trials (RCTs) are considered the gold standard, but no consensus exists on how and when they should be deployed to best meet the needs of all stakeholders. The agreed-upon workshop conclusions provide a basis for key considerations while undertaking future drug development activities for children with poor-prognosis cancers, ensuring that the needs and perspectives of all stakeholders are factored in from the outset.

Read More

US FDA approval of pediatric artificial intelligence and machine learning–enabled medical devices

12/21/24 at 03:40 AM

US FDA approval of pediatric artificial intelligence and machine learning–enabled medical devicesJAMA Pediatrics; Ryan C. L. Brewster, MD; Matthew Nagy, MD, MPH; Susmitha Wunnava, PhD; Florence T. Bourgeois, MD, MPH; 12/24Despite rapid growth in the availability of AI/ML [artificial intelligence and machine learning]-enabled devices in recent years, only a small number have been authorized for pediatric use. The current regulatory framework may expose children to off-label use, differential performance of algorithms, and safety risks. Additionally, the lack of standardized reporting of pediatric device characteristics precludes informed decision-making by health care clinicians on appropriate device use. Pediatric AI/ML-enabled devices should be validated using representative datasets and should include complete and standard documentation on pediatric testing and authorization. Such changes will require cooperation across regulatory and industry stakeholders with a commitment to safe, equitable, and effective AI/ML development for children. 

Read More

Loneliness and social and emotional support among sexual and gender minority caregivers

12/21/24 at 03:25 AM

Loneliness and social and emotional support among sexual and gender minority caregiversJAMA Network Open; Zhigang Xie, PhD; Hanadi Hamadi, PhD; Kassie Terrell, PhD; Laggy George, MPH; Jennifer Wells, BA; Jiaming Liang, PhD; 12/24In the current landscape of US health care, informal unpaid caregiving provided by family members and friends is indispensable for managing diseases and ensuring long-term care in residential settings. Sexual and gender minority (SGM) adults in the US are more likely than their non-SGM counterparts to provide informal care to their family members and/or friends. Caregiving can impose substantial physical, mental, and social connection issues on caregivers.Conclusions and Relevance In this cross-sectional study of social connections, SGM adults experienced significantly higher levels of loneliness compared with straight adults, irrespective of caregiving status. 

Read More

Developing evidence-based health policy for dementia care

12/21/24 at 03:20 AM

Developing evidence-based health policy for dementia careJAMA Health Forum; Katherine Baicker, PhD; Kosali Simon, PhD; 12/24The rising prevalence of Alzheimer disease and related dementias (ADRD) represents a profound challenge to health care and long-term care systems. Promising diagnostic tools, medicines, and interventions for ADRD are on the horizon, but these medical advances will come with substantial costs. By 2050, the annual cost of care for patients with ADRD is projected to reach $1.5 trillion in the US, with 75% covered by Medicaid and Medicare. In addition to payment policy, the decision-making environment (what, when, and how information is presented and the way that different choices are framed) for both patients and clinicians will determine the quality and value of care delivered and how that varies across patient populations. With a rapidly aging population and rising prevalence of ADRD, the need for these efforts is urgent.

Read More